Five‐year survival of resectable stage IIIA non‐small cell lung cancer in Brazil
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Maria Laura Gritti Paes de Barros und 5 weiteren Autor:innen. Beteiligte Einrichtung: Santa Marcelina Medicine School, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
In stage IIIA non‐small cell lung cancer (NSCLC), surgery plays a role in terms of multimodal treatment. Surgery rates have increased in recent years, mainly due to the combination of more accurate imaging tools, electromagnetic navigation bronchoscopy, robotic bronchoscopy, robotic surgery, and a wide range of challenging clinical scenarios to lead surgeons and oncologists to include surgery as an option in therapeutic management.
Objectives
To assess the prognostic factors, the 5‐year overall survival (OS) and cancer‐specific survival (CSS) of patients with resectable stage III‐NSCLC.
Methods
Patients' information was extracted from 76 Hospitals' Cancer Registry. OS and CSS were constructed using the Kaplan–Meier method, and the log‐rank test was used to assess differences between curves. In addition, Cox regression was conducted to evaluate the patients' characteristics leading to better OS and CSS.
Results
Overall, 433 stage III NSCLC surgical patients followed over 19 years were included. The median age was 61.29 ± 9.62 years, 58.4% male, 50.1% with adenocarcinoma, 29.3% with squamous cell carcinoma, 3.7% with large‐cell lung carcinoma, and 16,9% with other lung cancer types. The 5‐year OS was 30.6% (95% confidence interval [CI]: 27.4–36.1), and the CSS was 35.0% (95% CI: 29.4–41.0). In the Cox multivariate regression, squamous cell carcinoma was associated with reduced OS (hazard ratio [HR]: 1.40; 95% CI: 1.07–1.83; p =0.014) and CSS (HR: 1.56; 95% CI: 1.17–2.08; p = 0.002), in comparison with adenocarcinoma. The 2015–2019 quinquennial had a 50% reduction in HR (0.49; 95% CI: 0.29–0.81; p = 0.006), and the 2010–2014 group had a 40% reduction (0.59; 95% CI: 0.42–0.83; p = 0.006) in comparison with the 2000–2004 patients' group.
Conclusion
The OS and CSS of patients with resectable stage III NSCLC have improved over the past 19 years in our region. Squamous cell carcinoma was associated with increased mortality risk from any cause or specific cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Santa Marcelina Medicine School, Sao Paulo, Brazil.
- Oswaldo Cruz German Hospital, Sao Paulo, Brazil.
- Sao Paulo Oncocentro Foundation, Sao Paulo, Brazil.
- Hospital Alemão Oswaldo Cruz, Sao Paulo, Brazil.
- Hospital Santa Marcelina, Sao Paulo, Brazil.
Zitieren
APA
de Barros, M. L. G. P., Silva, V. G., Moreira, F. R., Perez, S. V., Younes, R. N., & Abrão, F. C. (2023). Five‐year survival of resectable stage IIIA non‐small cell lung cancer in Brazil. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27394
Vancouver
de Barros MLGP, Silva VG, Moreira FR, Perez SV, Younes RN, Abrão FC. Five‐year survival of resectable stage IIIA non‐small cell lung cancer in Brazil. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27394
BibTeX
@article{deBarros2023,
author = {de Barros, Maria Laura Gritti Paes and Silva, Vinícius G and Moreira, Frederico Rafael and Perez, Stela V and Younes, Riad N and Abrão, Fernando Conrado},
title = {Five‐year survival of resectable stage IIIA non‐small cell lung cancer in Brazil},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27394}
}
EUVIMED